国产氯吡格雷在冠心病合并糖尿病患者冠状动脉支架术后的临床应用

摘要

Objective To evaluate the safety and efficacy of domestic clopidogrel (Talcom) in patients with coronary artery disease and diabetes mellitus.Methods 168 patients who hospitalized for coronary artery disease and successfully received coronary stenting were divided into Talcom group (n=73) and Plavix (imported clopidogrel as control) group (n=95).The incidence of major adverse cardiac events (MACE) and bleeding between the two groups were compared in 6 months follow-up after operation.Results There were no significant difference about the incidence of MACE and bleeding between the two groups after 6 months follow-up.Conclusion The efficacy and safety of domestic clopidogrel (Talcom) is similar to that of imported clopidogrel (Plavix).%目的 评价国产氯吡格雷在冠心病合并糖尿病患者冠脉支架术后临床应用的疗效和安全性.方法 连续选取冠心病合并糖尿病并成功接受冠状动脉支架术的患者168例,其中术后接受国产氯吡格雷(泰嘉)的患者73例(泰嘉组),接受进口氯吡格雷(波立维)的患者95例(波立维组).术后进行6个月临床随访,观察两组患者主要不良心血管事件和出血事件的发生率.结果 术后两组患者主要不良心血管事件的发生率分别为15.1%和12.6%,出血事件的发生率分别为4.1%和6.3%,差异均无统计学意义.结论 国产与进口氯吡格雷在冠心病合并糖尿病患者冠脉支架术后的疗效和安全性方面作用相似.